Back to results
US 7,465,441 B2Granted
Use of gp130 activators in diabetic neuropathy
AssigneeLaboratoires Serono SA
InventorsMichel Dreano, Pierre-Alain Vitte
Life of this patent
Estimating the term…
Abstract
The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.
Claims17
A method for treating diabetic neuropathy, comprising administering an effective amount of a substance signalling through gp130 to a patient in need thereof, wherein said substance is:
- a) interleukin-6 (IL-6);
- b) a fragment of a) which binds to gp80 and initiates signaling through gp130;
- c) a variant of a) which has at least 90% sequence identity with a) and which initiates signaling through gp130;
- or
- d) a salt or functional derivative of a), b) or c) which initiates signaling through gp130 .
2 more elements
Dependencies are inferred from the claim text.